Railway Pension Investments Ltd Trims Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Railway Pension Investments Ltd trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 20.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 109,000 shares of the biopharmaceutical company’s stock after selling 28,700 shares during the quarter. Railway Pension Investments Ltd’s holdings in Regeneron Pharmaceuticals were worth $78,321,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of REGN. Bank Julius Baer & Co. Ltd Zurich boosted its position in shares of Regeneron Pharmaceuticals by 91,386.5% in the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 74,501,081 shares of the biopharmaceutical company’s stock worth $53,532,007,000 after purchasing an additional 74,419,647 shares in the last quarter. BlackRock Inc. boosted its holdings in Regeneron Pharmaceuticals by 2.7% in the first quarter. BlackRock Inc. now owns 9,418,300 shares of the biopharmaceutical company’s stock worth $7,738,735,000 after acquiring an additional 251,483 shares in the last quarter. EP Wealth Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $434,000. Dodge & Cox raised its position in shares of Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Dodge & Cox now owns 2,384,701 shares of the biopharmaceutical company’s stock worth $1,959,437,000 after purchasing an additional 161,642 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Regeneron Pharmaceuticals by 0.5% in the 1st quarter. Geode Capital Management LLC now owns 2,217,993 shares of the biopharmaceutical company’s stock worth $1,818,766,000 after purchasing an additional 10,003 shares in the last quarter. Institutional investors own 84.15% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $827.90, for a total transaction of $82,790.00. Following the completion of the transaction, the director now owns 18,547 shares of the company’s stock, valued at approximately $15,355,061.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $783.91, for a total transaction of $783,910.00. Following the sale, the executive vice president now owns 19,803 shares in the company, valued at approximately $15,523,769.73. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Tuesday, November 7th. The shares were sold at an average price of $827.90, for a total transaction of $82,790.00. Following the completion of the sale, the director now directly owns 18,547 shares in the company, valued at approximately $15,355,061.30. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 21,838 shares of company stock worth $18,294,246. Insiders own 8.83% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on REGN. Oppenheimer lifted their target price on shares of Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the stock a “market perform” rating in a report on Monday, August 21st. Barclays upped their price objective on Regeneron Pharmaceuticals from $900.00 to $925.00 and gave the company an “overweight” rating in a research report on Monday, August 21st. Westpark Capital assumed coverage on Regeneron Pharmaceuticals in a report on Friday, September 15th. They set a “hold” rating on the stock. Royal Bank of Canada decreased their target price on Regeneron Pharmaceuticals from $847.00 to $837.00 and set a “sector perform” rating for the company in a research report on Friday, November 3rd. Finally, BMO Capital Markets upped their target price on shares of Regeneron Pharmaceuticals from $960.00 to $985.00 and gave the company an “outperform” rating in a research note on Monday, August 21st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and twenty have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $903.64.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN traded down $4.71 during mid-day trading on Tuesday, reaching $796.93. The company’s stock had a trading volume of 34,115 shares, compared to its average volume of 563,039. The stock has a fifty day moving average of $816.88 and a two-hundred day moving average of $781.84. The firm has a market capitalization of $86.83 billion, a PE ratio of 22.86, a P/E/G ratio of 3.00 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a 52 week low of $668.00 and a 52 week high of $853.97. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.18 and a quick ratio of 4.47.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported $11.59 earnings per share for the quarter, topping the consensus estimate of $9.58 by $2.01. Regeneron Pharmaceuticals had a return on equity of 18.61% and a net margin of 30.47%. The business had revenue of $3.36 billion during the quarter, compared to the consensus estimate of $3.23 billion. During the same period in the prior year, the company posted $9.98 EPS. The firm’s revenue for the quarter was up 14.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.55 EPS for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.